Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update

SOLAIRIA-1 and SOLAIRIA-2 Phase 3 trials for GB-0895 (anti-TSLP) in severe asthma are advancing, with patient recruitment now underway across all six global regions. The update is incremental but supportive of clinical progress toward potential late-stage readouts.

Analysis

SOLAIRIA-1 and SOLAIRIA-2 Phase 3 trials for GB-0895 (anti-TSLP) in severe asthma are advancing, with patient recruitment now underway across all six global regions. The update is incremental but supportive of clinical progress toward potential late-stage readouts.